



Efficacy Study Summary of the D6 STERIONZER™ against surface SARS-CoV-2

Project	Surface SARS-CoV-2
Product	D6 BIPOLAR NEEDLEPOINT IONIZER
Laboratory Project #	1047
Testing Facility	Innovative Bioanalysis, Inc
Study Dates	04/06/2021 – 06/10/2021
GLP Compliance	All internal SOPs and processes follow GCLP guidelines and recommendations.
Test Substance	SARS-CoV-2 USA-CA1/2020
Description	Provided a D6 compact bipolar needlepoint-ionizing device designed to be integrated into an air movement system such as an HVAC ductsystem, air conditioner or humidifier. The in vitro study evaluates the efficacy of the D6 against SARS-CoV-2 on surfaces.
Test Conditions	The study conducted two control tests and 3 viral challenges in a certified Biosafety hood inside a BSL-3 laboratory. The temperature during testing was approximately 73 ±2°F, with a relative humidity of 44%. Slide samples were collected after 0, 15 and 30-minute exposure to the operating device.
Test Results	Active SARS-CoV-2 concentrations on the sample surfaces were reduced at the 15-minute and 30-minute time point. After 15 minutes of operation, the trial observed a decrease in the initial viral concentration of 6.32×10^6 to an average of 9.61×10^5 TCID50/ml and after 30 minutes to an average of 6.53×10^3 TCID50/ml.

<i>Exposure Time</i>	<i>Reduction in %</i>
15 minutes	84.80
30 minutes	99.90

Conclusion	The D6 demonstrated the ability to reduce the concentration of the active pathogen SARS-CoV-2 on surfaces when exposed to a negative and positive ion concentration.
-------------------	--

DocuSigned by:

Kevin Noble

5DF2797BAA78421...

9/7/2021

Kevin Noble
 Laboratory Director, Innovative Bioanalysis, Inc.

Date